Blog

[:content [\D \r \u \g \space \a \g \e \n \c \i \e \s \space \h \a \v \e \space \b \e \e \n \space \o \r \d \e \r \e \d \space \t \o \space \m \a \k \e \space \c \h \a \n \g \e \s \space \t \o \space \h \o \w \space \t \h \e \y \space \a \p \p \r \o \v \e \space \n \e \w \space \t \r \e \a \t \m \e \n \t \s \space \f \o \r \space \u \s \e \space \o \n \space \t \h \e \space \N \H \S \space \i \n " ..."]]

[:content [\T \h \e \space \m \i \n \u \t \e \s \space \f \r \o \m \space \t \h \e \space \N \o \v \e \m \b \e \r \space \2 \0 \1 \3 \space \P \T \A \C \space \m \e \e \t \i \n \g \space \w \e \r \e \space \p \u \b \l \i \s \h \e \d \space \o \n \space \t \h \e \space \P \H \A \R \M \A \C \space \w \e \b \s \i \t \e \space \o \n \space \1 \1 \space \F \e \b \r \u \a \r \y \. \space \  \T \h \e \space \o \u \t \c \o \m \e \s \space \f \r \o \m " ..."]]

CADTH has received notice of a pending submission from Novartis for Entresto (sacubitril with valsartan) for patients with NYHA class III-IV ...

[:content [\L \e \g \i \s \l \a \t \i \o \n \space \t \o \space \e \n \a \b \l \e \space \t \h \e \space \i \n \t \r \o \d \u \c \t \i \o \n \space \o \f \space \r \e \f \e \r \e \n \c \e \space \p \r \i \c \i \n \g \space \a \n \d \space \p \r \o \- \g \e \n \e \r \i \c \space \i \n \i \t \i \a \t \i \v \e \s \space \h \a \s \space \n \o \w \space \b \e \e \n \space \p \a \s \s \e \d \space \b \y \space \b \o \t \h \space \h \o \u \s \e \s \space \o \f \space \I \r \e \l \a \n \d \' \s " ..."]]

In the preliminary guidance, uncertainties in the company’s data mean that the committee proposes not to recommend obinutuzumab combination therapy ...

[:content [\1 \1 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \  \P \H \A \R \M \A \C \space \i \s \space \s \e \e \k \i \n \g \space \f \e \e \d \b \a \c \k \space \o \n \space \a \space \p \r \o \p \o \s \a \l \space \t \o \space \w \i \d \e \n \space \a \c \c \e \s \s \space \t \o \space \t \o \c \i \l \i \z \u \m \a \b \space \( \A \c \t \e \m \r \a \) \space \i \n \space \D \H \B \space \h \o \s \p \i \t \a \l \s \space \f \r \o \m " ..."]]

The Abbott Government today announced a further $75 million commitment to list three new drugs on the Pharmaceutical Benefits Scheme ...

PHARMAC is pleased to announce the approval of an agreement with Roche Products (NZ) Limited to widen access to tocilizumab ...

[:content [\2 \space \J \a \n \u \a \r \y \space \2 \0 \1 \4 \  \- \space \B \a \y \e \r \space \s \u \f \f \e \r \e \d \space \a \space \s \e \t \b \a \c \k \space \i \n \space \i \t \s \space \h \o \m \e \space \m \a \r \k \e \t \space \o \f \space \G \e \r \m \a \n \y \  \o \n \space \T \h \u \r \s \d \a \y \space \w \h \e \n \space \a \space \h \e \a \l \t \h \c \a \r \e \space \c \o \s \t \space \w \a \t \c \h \d \o \g \space \s \a \i \d " ..."]]

Announced in October by George Freeman MP, the minister responsible for NICE, the review will look in detail at the ...

[:content [\7 \space \M \a \r \c \h \space \2 \0 \1 \4 \space \- \space \T \h \e \space \l \i \n \k \s \space \t \o \space \t \h \e \space \P \u \b \l \i \c \space \S \u \m \m \a \r \y \space \D \o \c \u \m \e \n \t \s \space \f \o \r \space \t \h \e \  \r \e \c \o \m \m \e \n \d \a \t \i \o \n \s \space \a \n \d \space \s \u \b \s \e \q \u \e \n \t \space \r \e \j \e \c \t \i \o \n \s \space \f \r \o \m \  \t \h \e \space \P \B \A \C \space \m \e \e \t \i \n \g \space \h \e \l \d " ..."]]

[:content [\1 \7 \space \D \e \c \e \m \b \e \r \space \2 \0 \1 \3 \space \- \  \P \H \A \R \M \A \C \space \i \s \space \p \l \e \a \s \e \d \space \t \o \space \a \n \n \o \u \n \c \e \space \d \e \c \i \s \i \o \n \s \space \r \e \l \a \t \e \d \space \t \o \space \t \h \e \space \N \a \t \i \o \n \a \l \space \I \m \m \u \n \i \s \a \t \i \o \n \space \S \c \h \e \d \u \l \e \space \t \h \a \t \space \w \i \l \l \space \t \a \k \e \space \e \f \f \e \c \t \space \f \r \o \m " ..."]]

Updated PBS Price Disclosure Arrangements Procedural and Operational Guidelines are available on the Price Disclosure (SPD) page of the PBS website.  A Cycles Table, ...

Estimated savings achieved through PHARMAC’s tender of off-patent medicines have now topped $600 million. ...